PASADENA, Calif., Nov. 12, 2015 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the largest and leading urban office REIT uniquely focused on collaborative science and technology campuses in AAA urban innovation cluster locations, announced today that Joel S. Marcus, chairman, chief executive officer and founder, was honored with the NY/NJ CEO Lifetime Achievement Award in recognition of his leadership in the life science community. Mr. Marcus received the award on Wednesday, Nov. 11 during the NY/NJ CEO Conference, hosted by Boston Biotech Conferences, at the Apella™ event space at the Alexandria Center® for Life Science – New York City. The award was presented by esteemed past award honorees Marc Tessier-Lavigne, Ph.D., president of The Rockefeller University; Ron Cohen, M.D., president and chief executive officer of Acorda Therapeutics, Inc. and George Yancopoulos, M.D., Ph.D., founding scientist, president and chief scientific officer of Regeneron Pharmaceuticals, Inc.
Mr. Marcus was nominated and elected by conference participants representing some of the most influential biotechnology companies, venture capital firms and leading healthcare organizations internationally. The honor recognizes the recipient's extraordinary contributions toward advancing the life science industry and breakthrough products that address unmet medical needs, as well as helping to create an environment that fosters the growth of the industry in the New York metropolitan area. Mr. Marcus and Alexandria have been a longstanding partner to the global life science community, providing core infrastructure and collaborative environments, while facilitating the expansion of the New York City life science cluster.
Dr. Tessier-Lavigne, trusted advisor to Alexandria Real Estate Equities, Inc., said, "I have had the pleasure of knowing Joel and his team for many years. Under Joel's vision and leadership, Alexandria has become a driving force in the life science ecosystem in New York, as well as an integral partner in each of its world-class urban clusters across the country. Alexandria provides support for start-up companies, facilitates policy-changing dialogue with leaders of industry, academia, payers and providers, and creates communities at the leading edge of collaboration – all in the cities where scientific discoveries and technological advances are happening every day. I am delighted to see him recognized with this well-deserved award."
"For over 20 years, we have been building the future of life-changing innovation through our unique urban innovation clusters, venture investments, thought leadership forums like the Alexandria Summit and support for multiple programs and events in the life science industry. We take pride that Alexandria is more than just a real estate company – we are a collaborative partner with our client tenants, which represent some of the world's leading biotechnology and pharmaceutical companies. We also support entrepreneurial companies through Alexandria Venture Investments, which provides strategic investment capital to the science and technology industries," said Mr. Marcus. "I am greatly honored by this recognition, which reflects our entire team's dedication and contribution to creating thriving innovation clusters throughout the United States, especially in New York City. We are at an unprecedented time in life science innovation, and we look forward to continuing our commitment to this mission-critical industry, which strives to transform medicine to improve patient lives everywhere."
About the Boston Biotech Conferences
The Boston Biotech Conferences (BBC)'s mission is to build a vibrant community of biopharma leaders, which will help to drive biopharma innovation in biotech, by convening leaders across industry and academia. The conferences are exclusive, thought-leader forums for senior biopharma executives. Each conference is highly interactive and co-hosted by healthcare industry leaders to foster discussions and facilitate information-sharing, networking, and corporate development within the biopharma community.
About Alexandria Real Estate Equities, Inc. (NYSE: ARE)
Alexandria Real Estate Equities, Inc. (NYSE: ARE) is the largest and leading urban office REIT uniquely focused on collaborative science and technology campuses in AAA innovation cluster locations with a total market capitalization of $10.8 billion as of September 30, 2015, and an asset base of 31.5 million square feet, including 19.9 million RSF of operating properties and development and redevelopment projects under construction, as well as an additional 11.6 million square feet of near-term and future ground-up development projects. Alexandria pioneered this niche in 1994 and has since established a dominant market presence in key locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle Park. Alexandria is known for its high-quality and diverse client tenant base, with approximately 53% of total annualized base rent as of September 30, 2015, generated from investment-grade client tenants – a REIT industry-leading percentage. Alexandria has a longstanding and proven track record of developing Class A assets clustered in urban science and technology campuses that provide its innovative client tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. For more information, please visit www.are.com.
SOURCE Alexandria Real Estate Equities, Inc.